The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases

Table 4

Comparison between PCPT and REDUCE.

	PCPT	REDUCE
Sponsor	South West Oncology Group	GalxoSmithKline
Duration	7 years	4 years
Risk of CaP in participants	lower	higher
No. of participants	18,882 randomized; 9060 included in final analysis	8122 randomized
Age	≥55 years	50–75 years
Entry serum PSA	≤3.0 ng/mL	2.5–10 ng/mL
Baseline biopsies	No	Yes (6–12 cores) within 6 months prior to enrollment
Study-mandated biopsies	Year 7	Years 2 and 4
Study-mandated biopsy cores	≥6 (6 cores in nearly 80%)	10 (83% had at least 1 biopsy)
Overall relative risk reduction in CaP versus placebo	25%	23%
Incidence of Gleason sum ≥7 CaP	↑26% (6.4% in finasteride versus 5.1% in placebo), 𝑃<0.05	Same (6.7% in dutasteride versus 6.8%: in placebo)
Incidence of Gleason sum ≥8 CaP	↑91% (2.1% in finasteride versus 1.1% in placebo), 𝑃<0.05	Same over 4 years (0.9% in dutasteride versus 0.6% in placebo); however, in years 3-4, there were 12 GS ≥8 CaP in dutasteride group (0.5%) versus 1 in placebo group (<0.1%), 𝑃<0.05